Tatsuya Masuda, Tomoo Daifu, Masamitsu Mikami, Hiroshi Sugiyama* and Yasuhiko Kamikubo*
Malignant Rhabdoid Tumor (MRT) is a quite rare malignant pediatric disease that occurs primarily in infants and young children. Although most patients with MRT are treated with the intensive multimodal treatment, the results are unsatisfied and there is no established standard of care for MRT. Therefore, there is a great need for more effective treatment(s) for MRT. Recently, we have demonstrated that RUNX1 silencing and “CROX (Cluster Regulation of RUNX)” strategy using our novel RUNX inhibitor (Chb-M') strongly reduce MRT cell proliferation rate via the augmentation of p53-mediated apoptotic pathway in vitro and in vivo. In this mini-review, we describe the molecular characteristics of our RUNX inhibitor, DNA-alkylating Pyrrole-Imidazole (PI) polyamides, and its anti-tumor effects on a variety of cancers including MRT. Finally, we discuss the precise molecular mechanisms behind p53-mediated apoptosis induced by RUNX inhibition in MRT cells.
HTML PDFShare this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report
